AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult patients (age\> 18 years) treated with myeloablative or non-myeloablative HSCT in outpatient follow-up without recurrent disease are eligible for inclusion.
Locations
Other Locations
Denmark
Rigshospitalet
RECRUITING
Copenhagen
Contact Information
Primary
Mette Schaufuss Engedal, MSc
mette.schaufuss.engedal@regionh.dk
+45 51896699
Backup
Mary Jarden
mary.jarden@regionh.dk
+4535454368
Time Frame
Start Date: 2024-11-01
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 100
Treatments
Experimental: Intervention group
The intervention is a stepped-care multi-modal intervention and consists of 4 steps, including screening for vulnerability, digital health support and education. Individual consultations based on PRO data (HM-PRO) and multidisciplinary late effects management based on PRO assessment. The multidisciplinary team will consist of nurses, hematologists, physiotherapists, social workers, and dietitians.
No_intervention: Control Group
Patients in the control group will receive usual care
Related Therapeutic Areas
Sponsors
Leads: Rigshospitalet, Denmark
Collaborators: Danish Cancer Society